This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by BOUCHER, A. Articles by STE-MARIE, L. G. Search for Related Content PubMed PubMed Citation Articles by BOUCHER, A. Articles by STE-MARIE, L. G.

Estrogen Replacement Decreases the Set Point of Parathyroid Hormone Stimulation by Calcium in Normal Postmenopausal Women^*

André-Viallet Clinical Research Center, Hôpital Saint-Luc, and Departments of Medicine, Obstetrics (P.F.), Pharmacology (M.G.-B.), and Medical Biochemistry (R.L.), Université de Montreal Montreal, Quebec, Canada H3C3J7

Address requests for reprints to: Pierre D’Amour, M.D., Centre de Recherche Clinique André-Viallet, 264 René-Lévesque Boulevard East, Montreal, Quebec, Canada H2X 1P1.

Estrogens decrease serum total and ionized calcium (Ca) concentrations in postmenopausal women with or without primary hyperparathyroidism, but cause little or no increase in serum PTH suggesting a modification of the relationship between the two. In order to define this relationship, we studied the effect of conjugated estrogens on total and ionized serum Ca and serum PTH concentrations in five normal postmenopausal women, before and after 3, 11, and 23 weeks of therapy. Dynamic tests of parathyroid gland function, based on 2-h iv infusions of CaCl₂ and NaEDTA, were performed at each time. Total and ionized serum Ca and carboxylterminal PTH were measured every 15 min during the infusions, and parathyroid function was evaluated by a nonlinear 4-parameter mathematical model. Estrogen therapy caused decreases in serum total [2.36 ± 0.04 (SD) mmol/L, baseline vs. 2.19 ± 0.05 mmol/L, 23 weeks, P < 0.005) and ionized calcium (1.27 ± 0.01 mmol/L, baseline vs. 1.21 ± 0.02 mmol/L, 23 weeks, P < 0.005]; the decreases were evident at 3 weeks and persisted for the duration of the study. Serum PTH concentrations did not change (8.94 ± 1.84 pmol/L, baseline vs. 8.98 ± 2.38 pmol/L, 23 weeks). Three parameters of the parathyroid function, the maximal response to hypocalcemic stimulation, the nonsuppressible fraction of circulating PTH, and the slope of PTH on calcium at the set point were not affected by estrogen treatment. The fourth parameter, the set point of PTH stimulation by serum total calcium (2.16 ± 0.04 mmol/L, baseline vs. 1.97 ± 0.07 mmol/L, 23 weeks, P < 0.0166) or by serum ionized Ca (1.19 ± 0.04 mmol/L, baseline vs. 1.12 ± 0.03 mmol/L, 23 weeks, P < 0.01), was decreased by estrogen treatment. This was evident at the earliest time point studied and persisted thereafter. The decrease in ionized Ca set point only explained 40% of the decrease in total calcium set point, the remaining 60% being related to hemodilution of plasma protein during therapy. We conclude that estrogen replacement can influence parathyroid function in postmenopausal women by resetting the set point of PTH stimulation by ionized Ca. This in turn could contribute to the estrogeninduced changes in their Ca balance

^* This study was supported by Grant MA-7643 from the Medical Research Council of Canada and a grant from The Ayerst Company, Montreal, through Dr. Bernard Leduc, Director of Clinical Research.

Received August 22, 1988.

This article has been cited by other articles:

				A. J. Felsenfeld, M. Rodriguez, and E. Aguilera-Tejero Dynamics of Parathyroid Hormone Secretion in Health and Secondary Hyperparathyroidism Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1283 - 1305. [Abstract] [Full Text] [PDF]

				I. Titon, A. Cailleux-Bounacer, J. P. Basuyau, H. Lefebvre, A. Savoure, and J. M. Kuhn Evaluation of a standardized short-time calcium suppression test in healthy subjects: interest for the diagnosis of primary hyperparathyroidism Eur. J. Endocrinol., September 1, 2007; 157(3): 351 - 357. [Abstract] [Full Text] [PDF]

				E. M. Brown Medical Therapy of Primary Hyperparathyroidism: Are We There Yet? IBMS BoneKEy, August 1, 2005; 2(8): 5 - 8. [Full Text] [PDF]

				K. Michaelsson, J. A. Baron, B. Y. Farahmand, and S. Ljunghall Influence of Parity and Lactation on Hip Fracture Risk Am. J. Epidemiol., June 15, 2001; 153(12): 1166 - 1172. [Abstract] [Full Text] [PDF]

				R. Mihai and J. R. Farndon Parathyroid disease and calcium metabolism Br. J. Anaesth., July 1, 2000; 85(1): 29 - 43. [Full Text] [PDF]

				J. S. Finkelstein and D. A. Schoenfeld Effects of Gonadal Suppression on the Regulation of Parathyroid Hormone and 1,25-Dihydroxyvitamin D Secretion in Women J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2151 - 2156. [Abstract] [Full Text]